Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000816279 | SCV000956780 | likely benign | Rhabdoid tumor predisposition syndrome 2 | 2023-08-19 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002453855 | SCV002615333 | uncertain significance | Hereditary cancer-predisposing syndrome | 2020-01-09 | criteria provided, single submitter | clinical testing | The c.3547-3C>T intronic variant results from a C to T substitution 3 nucleotides upstream from coding exon 25 in the SMARCA4 gene. This nucleotide position is not well conserved in available vertebrate species. Using two different splice site prediction tools, this alteration is predicted by ESEfinder to slightly weaken the efficiency of the native splice acceptor site, but is not predicted to have a deleterious effect on this splice acceptor site by BDGP; however, direct evidence is unavailable. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |